Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

FATE

+ Watchlist+ Portfolio

Fate Therapeutics, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.02
52-Week Range
$0.95 – $3.23
Market Cap
$127.76M
P/E (TTM)
—
EPS (TTM)
-1.03
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.96
PEG Ratio
—
Return on Equity
-67.79%
Return on Assets
-27.92%
Gross Margin
0.00%
Operating Margin
-2736.88%
Profit Margin
0.00%
Current Ratio
4.41
Debt/Equity
0.56
Total Debt
$74.49M
Free Cash Flow
$-50.73M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$63.01M

Market Snapshot

About

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs), which offer the potential for mass production and immediate availability. Fate Therapeutics has a pipeline of CAR T-cell and CAR NK-cell product candidates targeting various hematologic malignancies and solid tumors. The company's proprietary iPSC product platform is designed to overcome limitations of patient-specific cell therapies and enable more scalable manufacturing.